Literature DB >> 22997458

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Baccarani1, S Pileri, J-L Steegmann, M Muller, S Soverini, M Dreyling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22997458     DOI： 10.1093/annonc/mds228

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  20 in total

Review 1.  Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.

Authors:  Marjan Yaghmaie; Cecilia Cs Yeung
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

2.  Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients.

Authors:  Siti Maziras Makhtar; Azlan Husin; Abdul Aziz Baba; Ravindran Ankathil
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

3.  Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.

Authors:  Aaron N Winn; Nancy L Keating; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 4.  A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.

Authors:  Valentin García-Gutiérrez; Massimo Breccia; Elias Jabbour; Michael Mauro; Jorge E Cortes
Journal:  J Hematol Oncol       Date:  2022-07-11       Impact factor: 23.168

Review 5.  Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512

Review 6.  [Current diagnostic requirements in chronic myeloid leukemia].

Authors:  Thomas Lion; Gerald Webersinke; Ulrike Kastner; Christoph Seger; Gerlinde Mitterbauer-Hohendanner; Günther Gastl
Journal:  Wien Med Wochenschr       Date:  2013-10-01

7.  Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.

Authors:  Christel C L M Boons; Eleonora L Swart; Lonneke Timmers; Peter M van de Ven; Jeroen J W M Janssen; Jacqueline G Hugtenburg
Journal:  BMC Cancer       Date:  2014-04-08       Impact factor: 4.430

8.  Complex variant of Philadelphia translocation involving chromosomes 9, 12, and 22 in a case with chronic myeloid leukaemia.

Authors:  F Malvestiti; C Agrati; S Chinetti; A Di Meco; S Cirrincione; M Oggionni; B Grimi; F Maggi; G Simoni; F R Grati
Journal:  Case Rep Genet       Date:  2014-06-18

9.  Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Authors:  Ursula Rochau; Martina Kluibenschaedl; David Stenehjem; Kuo Kuan-Ling; Jerald Radich; Gary Oderda; Diana Brixner; Uwe Siebert
Journal:  Leuk Res Treatment       Date:  2015-12-10

10.  Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Authors:  Koung Jin Suh; Ji Yun Lee; Dong-Yeop Shin; Youngil Koh; Soo-Mee Bang; Sung-Soo Yoon; Seonyang Park; Inho Kim; Jeong-Ok Lee
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.